782 related articles for article (PubMed ID: 24782550)
1. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
2. Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib.
Woodcock HV; Molyneaux PL; Maher TM
Drug Des Devel Ther; 2013; 7():503-10. PubMed ID: 23818761
[TBL] [Abstract][Full Text] [Related]
3. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
4. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
[TBL] [Abstract][Full Text] [Related]
5. Nintedanib in the treatment of idiopathic pulmonary fibrosis.
Mazzei ME; Richeldi L; Collard HR
Ther Adv Respir Dis; 2015 Jun; 9(3):121-9. PubMed ID: 25862013
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis.
Keating GM
Drugs; 2015 Jul; 75(10):1131-40. PubMed ID: 26063212
[TBL] [Abstract][Full Text] [Related]
7. Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib.
Bonella F; Stowasser S; Wollin L
Drug Des Devel Ther; 2015; 9():6407-19. PubMed ID: 26715838
[TBL] [Abstract][Full Text] [Related]
8. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience.
Rivera-Ortega P; Hayton C; Blaikley J; Leonard C; Chaudhuri N
Ther Adv Respir Dis; 2018; 12():1753466618800618. PubMed ID: 30249169
[TBL] [Abstract][Full Text] [Related]
9. Nintedanib: from discovery to the clinic.
Roth GJ; Binder R; Colbatzky F; Dallinger C; Schlenker-Herceg R; Hilberg F; Wollin SL; Kaiser R
J Med Chem; 2015 Feb; 58(3):1053-63. PubMed ID: 25474320
[TBL] [Abstract][Full Text] [Related]
10. Nintedanib (OFEV) in the treatment of idiopathic pulmonary fibrosis.
Fukihara J; Kondoh Y
Expert Rev Respir Med; 2016 Dec; 10(12):1247-1254. PubMed ID: 27744713
[TBL] [Abstract][Full Text] [Related]
11. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
[TBL] [Abstract][Full Text] [Related]
12. Nintedanib in idiopathic pulmonary fibrosis.
Woodcock HV; Maher TM
Drugs Today (Barc); 2015 Jun; 51(6):345-56. PubMed ID: 26261848
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of nintedanib, an inhibitor of tyrosine kinases, in patients with non-small cell lung cancer or idiopathic pulmonary fibrosis.
Schmid U; Liesenfeld KH; Fleury A; Dallinger C; Freiwald M
Cancer Chemother Pharmacol; 2018 Jan; 81(1):89-101. PubMed ID: 29119292
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib: A Review in Fibrotic Interstitial Lung Diseases.
Lamb YN
Drugs; 2021 Apr; 81(5):575-586. PubMed ID: 33765296
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update.
Rodríguez-Portal JA
Drugs R D; 2018 Mar; 18(1):19-25. PubMed ID: 29209910
[TBL] [Abstract][Full Text] [Related]
16. The safety and tolerability of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Cottin V
Expert Opin Drug Saf; 2017 Jul; 16(7):857-865. PubMed ID: 28571476
[TBL] [Abstract][Full Text] [Related]
17. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
[TBL] [Abstract][Full Text] [Related]
18. Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.
Wongkarnjana A; Yanagihara T; Kolb MR
Expert Rev Respir Med; 2019 Dec; 13(12):1139-1146. PubMed ID: 31564185
[No Abstract] [Full Text] [Related]
19. Population pharmacokinetics of nintedanib in patients with idiopathic pulmonary fibrosis.
Schmid U; Doege C; Dallinger C; Freiwald M
Pulm Pharmacol Ther; 2018 Feb; 48():136-143. PubMed ID: 29133080
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib - efficacy, safety and practical aspects of treatment for patients with idiopathic pulmonary fibrosis.
Martusewicz-Boros M; Górska K
Adv Respir Med; 2020; 88(6):599-607. PubMed ID: 33393653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
